Clinical Trial Update: Botulinum Toxin for the Treatment of Depression [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update investigating botulinum toxin for treating depression has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Major Depressive Disorder

Drugs mentioned

• Botulinum toxin (botulinum toxin)

Snippet

Sponsor: University Hospital, Basel, Switzerland | Conditions: Depression | Phase 2 | Status: COMPLETED